title: Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.
abstract: The serum pharmacokinetic profile of intravenous (i.v.) tobramycin administration was characterized for a sample of nine adult patients with cystic fibrosis (CF) who were hospitalized for an acute pulmonary exacerbation. Current recommended i.v. tobramycin dosing protocols are predicted through modeling and simulation to be suboptimal. Empirical tobramycin regimens of ≥15 mg/kg of body weight administered i.v. once daily should be evaluated for adult patients with CF to optimize outcomes.
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
authors.forename: Jill M
authors.initials: JM
authors.lastname: Butterfield
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Lodise
authors.forename: Scott
authors.initials: S
authors.lastname: Beegle
authors.forename: Jonathan
authors.initials: J
authors.lastname: Rosen
authors.forename: Joshua
authors.initials: J
authors.lastname: Farkas
authors.forename: Manjunath P
authors.initials: MP
authors.lastname: Pai
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D003550:Cystic Fibrosis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000097:blood / Q000188:drug therapy*; D014031:Tobramycin / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014031:Tobramycin
references.citation: Clin Pharm. 1983 May-Jun;2(3):262-4
references.pmid: 6883955
references.citation: Chest. 2004 Jan;125(1 Suppl):1S-39S
references.pmid: 14734689
references.citation: Chest. 1997 Nov 5;112(5):1208-13
references.pmid: 9367459
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):809-13
references.pmid: 10722474
references.citation: Hemodial Int. 2012 Jul;16(3):414-9
references.pmid: 22469183
references.citation: Antimicrob Agents Chemother. 1987 Apr;31(4):594-9
references.pmid: 3606063
references.citation: Ther Drug Monit. 2012 Aug;34(4):467-76
references.pmid: 22722776
references.citation: J Pediatr. 1984 Jul;105(1):117-24
references.pmid: 6376743
references.citation: J Antimicrob Chemother. 2006 Oct;58(4):822-9
references.pmid: 16885180
references.citation: Clin Microbiol Rev. 2002 Apr;15(2):194-222
references.pmid: 11932230
references.citation: Cochrane Database Syst Rev. 2013 May 31;(5):CD006682
references.pmid: 23728662
references.citation: Clin Microbiol Infect. 2010 Sep;16(9):1482-7
references.pmid: 20002107
references.citation: Antimicrob Agents Chemother. 2011 Jun;55(6):2528-31
references.pmid: 21402835
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4718-24
references.pmid: 15561849
references.citation: Eur Respir J. 2002 Feb;19(2):303-9
references.pmid: 11866010
references.citation: Diagn Microbiol Infect Dis. 2005 Jun;52(2):123-7
references.pmid: 15964500
references.citation: Respir Res. 2005 Jun 01;6:49
references.pmid: 15929792
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):2795-805
references.pmid: 22371890
references.citation: Antimicrob Agents Chemother. 1999 Mar;43(3):623-9
references.pmid: 10049277
references.citation: Clin Infect Dis. 2000 Mar;30(3):433-9
references.pmid: 10722424
references.citation: Thorax. 2007 Jun;62(6):541-5
references.pmid: 17234661